



CERTIFICATE OF MAIL UNDER 37 C.F.R. § 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450 on July 25, 2005.


John V. Hanley, Reg. No. 38,171

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the application of

Inventor: Johnston William McAvoy
and Coral Gwenda Chamberlain

Serial No. 08/648,092

Filed: May 17, 1996

For: A METHOD FOR PREVENTING OR
CONTROLLING CATARACT

Examiner: Z. Fay

Group Art Unit: 1614

Client ID/Matter No. UNSYD-39709

July 25, 2005

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to the duty of disclosure, Form PTO-1449 is enclosed in order to inform the Examiner of art which may be material to patentability of the invention. Copies of the U.S. patents are not enclosed although applicant will produce them upon examiner's request. (Pre-OG Notices, "Information Disclosure Statements May Be Filed Without Copies of U.S. Patents and Published Applications in Patent Applications Filed After June 30, 2003," from Deputy Commissioner Stephen Kunin, dated July 11, 2003.) The Examiner is requested to consider and cite the references in the examination.


A check in the amount of \$180.00 is enclosed to cover the fee under 37 CFR §1.17(p).

The Commissioner is authorized to charge any fee deficiency or credit any overpayment to

Deposit Account No. 06 2425. A duplicate copy of this paper is enclosed.

Respectfully submitted,

FULWIDER PATTON LEE & UTECHT, LLP

By: 
John V. Hanley
Registration No. 38,171

JVH/kst
Howard Hughes Center
6060 Center Drive, Tenth Floor
Los Angeles, CA 90045
Telephone: (310) 824-5555
Facsimile: (310) 824-9696
Customer No. 24201
96497.1

FORM PTO-1449 (Modified)				Docket No.: UNSYD-39709		Serial No.: 08/648,092	
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT				Applicant: Johnston William McAvoy et al.			
				Filing Date: May 17, 1996		Art Unit: 1614	
UNITED STATES PATENT DOCUMENTS							
*Exr's. Inits.	Cite #	Patent No.	Date	Name	Class	Sub Class	Filing Date (if applic- able)
		5,279,833	01/18/1994	Nicolaus			
		5,283,261	02/01/1994	Drago			
		5,284,874	02/08/1994	Clark et al.			
		5,290,813	03/01/1994	Clark et al.			
		5,338,545	08/16/1994	Clark et al.			
		5,399,573	03/21/1995	Garner et al.			
		5,401,880	03/28/1995	Clark et al.			
		5,519,054	05/21/1996	Santangelo et al.			
		5,589,464	12/31/1996	Garner et al.			
		5,665,770	09/09/1997	Terao et al.			
		5,686,487	11/11/1997	Ueno			
		5,827,862	10/27/1998	Yamamura et al.			
FOREIGN PATENT DOCUMENTS							
Exr's. Init.	Cite #	Document No.	Date	Country	Class	Sub	Translat ion? Yes No
OTHER REFERENCES (Including Author, Date, Title, Pertinent Pages, Etc.)							
Exr's. Inits.	Ref.	Bibliographic Data					
		Danielpour, et al., "Differential Inhibition of Transforming Growth Factor β 1 and β 2 Activity by α 2- Macroglobulin", The Journal of Biological Chemistry, Vol. 265, No. 12, Issue of April 25, pp. 6973-6977, 1990.					
		Wolf, Gunter, et al., "Angiotensin II-Induced Hypertrophy Of Cultured Murine Proximal Tubular Cells Is Mediated By Endogenous Transforming Growth Factor- β ", Journal of Clinical Investigation, 92(3):1366-72, 1993 September.					
		Slager HG., et al., "Secretion Of Transforming Growth Factor- β Isoforms By Embryonic Stem Cells: Isoform And Latency Are Dependent On Direction Of Differentiation", Journal of Cellular Physiology, 156(2):247-56, 1993 August.					
Examiner				Date Considered			
<p>* Examiner: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. ¶ 609. Draw line through citation (i.e., citation) if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>							

FORM PTO-1449 (Modified)				Docket No.: UNSYD-39709		Serial No.: 08/648,092	
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT				Applicant: Johnston William McAvoy et al.			
				Filing Date: May 17, 1996		Art Unit: 1614	
UNITED STATES PATENT DOCUMENTS							
*Exr's. Inits.	Cite #	Patent No.	Date	Name	Class	Sub Class	Filing Date (if applic- able)
FOREIGN PATENT DOCUMENTS							
Exr's. Init.	Cite #	Document No.	Date	Country	Class	Sub	Translat ion? Yes No
OTHER REFERENCES (Including Author, Date, Title, Pertinent Pages, Etc.)							
Exr's. Inits.	Ref.	Bibliographic Data					
		Kelley, J. et al., "Complex Cytokine Modulation of a Continuous Line of Mink Lung Epithelia Cells (Mv1Lu)", Experimental Lung Research, 18(6):877-87, 1992 November-December.					
		Phan, S. et al., "Regulation of Rat Pulmonary Artery Endothelial Cell Transforming Growth Factor- β Production by IL-1 β and Tumor Necrosis Factor- α_1 ", Journal of Immunology, 149(1):103-6, 1992 July 1.					
		Bang, YJ, et al., "Cyclic AMP Induces Transforming Growth Factor β_2 Gene Expression and Growth Arrest in the Human Androgen-Independent Prostate Carcinoma Cell Line PC-3", Proceedings of the National Academy of Sciences of the United States of America, 89(8):3556-60, 1991 April 15.					
		Ogawa, Y., et al., "Purification and Characterization of Transforming Growth Factor- β 2.3 and β 1.2 Heterodimers From Bovine Bone", Journal of Biological Chemistry, 267(4):2325-8, 1992 February 5.					
		Matsuzaki, N., et al., "Trophoblast-Derived Transforming Growth Factor- β_1 Suppresses Cytoline-Induced, But Not Gonadotropin-Releasing Hormone-Induced, Release of Human Chorionic Gonadotropin by Normal Human Trophoblasts", Journal of Clinical Endocrinology & Metabolism, 74(1):211-6, 1992 January.					
		Su, H., et al., "A Role For Transforming Growth Factor- β_1 in Regulating Natural Killer Cell and T Lumphocyte Proliferative Responses During Acute Infection With Lymphocytic Choriomeningitis Virus", Journal of Immunology, 147(8):2717-27, 1991 October 15.					
Examiner				Date Considered			
<p>* Examiner: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. ¶ 609. Draw line through citation (i.e., citation) if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>							

FORM PTO-1449 (Modified)				Docket No.: UNSYD-39709		Serial No.: 08/648,092	
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT				Applicant: Johnston William McAvoy et al.			
				Filing Date: May 17, 1996		Art Unit: 1614	
UNITED STATES PATENT DOCUMENTS							
*Exr's. Inits.	Cite #	Patent No.	Date	Name	Class	Sub Class	Filing Date (if applic- able)
FOREIGN PATENT DOCUMENTS							
Exr's. Init.	Cite #	Document No.	Date	Country	Class	Sub	Translat ion? Yes No
OTHER REFERENCES (Including Author, Date, Title, Pertinent Pages, Etc.)							
Exr's. Inits.	Ref.	Bibliographic Data					
		Phan, SH, et al., "Stimulation of Rat Endothelial Cell Transforming Growth Factor- β Production by Bleomycin", Journal of Clinical Investigation, 87(1):148-54, 1991 January.					
		Bristol, L., et al., "IL-1 α Induces Expression of Active Transforming Growth Factor- β in Nonproliferating T Cells Via a Post-Transcriptional Mechanism", Journal of Immunology, 145(12):4108-14, 1990 December 15.					
		Altman, DJ., et al., "A Transforming Growth Factor β 2 (TGF- β 2)-like Immunosuppressive Factor in Amniotic Fluid and Localization of TGF- β 2 mRNA in the Pregnant Uterus", Journal of Experimental Medicine, 172(5):1391-401, 1990 November 1.					
		Lucas, C., et al., "The Autocrine Production of Transforming Growth Factor- β 1 During Lymphocyte Activation. A Study With a Monoclonal Antibody-based ELISA", Journal of Immunology, 145(5):1415-22, 1990 September 1.					
		Jennings, John, et al., "Heterogeneity of Latent Transforming Growth Factor- β Isolated From Bone Matrix Proteins", Endocrinology, 126(2):1014-21, 1990 February.					
		Yamaguchi, Y., et al., "Negative Regulation of TGF β by the Proteoglycan Decorin", Nature, 1990; 346:281-284.					
		McCaffrey, T.A., et al., "Transforming Growth Factor- β 1 is a Heparin-Binding Protein: Identification of Putative Heparin-Binding Regions and Isolation of Heparins With Varying Affinity for TGF- β 1", Journal of Cellular Physiology, 152:430-440, 1992.					
Examiner					Date Considered		
* Examiner: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. ¶ 609. Draw line through citation (i.e., citation) if not in conformance and not considered. Include copy of this form with next communication to applicant.							

FORM PTO-1449 (Modified)				Docket No.: UNSYD-39709		Serial No.: 08/648,092	
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT				Applicant: Johnston William McAvoy et al.			
				Filing Date: May 17, 1996		Art Unit: 1614	
UNITED STATES PATENT DOCUMENTS							
*Exr's. Inits.	Cite #	Patent No.	Date	Name	Class	Sub Class	Filing Date (if applic- able)
FOREIGN PATENT DOCUMENTS							
Exr's. Init.	Cite #	Document No.	Date	Country	Class	Sub	Translat ion? Yes No
OTHER REFERENCES (Including Author, Date, Title, Pertinent Pages, Etc.)							
Exr's. Inits.	Ref.	Bibliographic Data					
		Bachman, W.G., et al., "Essential Ions For Maintenance of the Corneal Epithelial Surface", Invest Ophthalmol vis. Sci., 26:1484-1488, 1985.					
		Gilbard, J., et al., "Ophthalmic Solutions, the Ocular Surface, and a Unique Therapeutic Artificial Tear Formulation", American Journal of Ophthalmology 107:348-355, April 1989.					
		Edelhauser, Henry, Ph.D., et al., "Comparative Toxicity of Intraocular Irrigating Solutions on the Corneal Endothelium", American Journal of Ophthalmology, 81(4):473-481, 1976.					
		Hyndiuk, Robert A., M.D., et al., "Overview of the Corneal Toxicity of Surgical Solutions and Drugs; and Clinical Concepts in Corneal Edema", Lens and Eye Toxicity Research, 9:331-350, 1992.					
Examiner				Date Considered			
* Examiner: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. ¶ 609. Draw line through citation (i.e., citation) if not in conformance and not considered. Include copy of this form with next communication to applicant.							